News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Pozen, Inc. Reports PA32540 / PA8140 Updates and First Quarter 2012 Financial Results
May 1, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2012.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Layoffs
Biogen Shuffles 20 Staff After Ending AAV Work
September 29, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Genmab Buys Rising Cancer Star Merus for $8B
September 29, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Heidelberg Pharma Misses Out on Royalty Payment, Plans 75% Workforce Cut
September 26, 2025
·
1 min read
·
Dan Samorodnitsky
Job Trends
$100,000 H-1B Fee Leaves Biopharma Grappling With Impact
September 25, 2025
·
6 min read
·
Angela Gabriel
